bioscience atlas 2008€¦ · hoffman laroche, inc – the u.s. prescrip-tion drug unit of the...

BIOSCIENCE

ATLAS2008

here can you find the leaders and innovators at the forefront of bioscience? The 2008 BioScience Atlas profiles a number of areas rapidly advancing in this prestigious life science field. These regions promise strong

growth and initiative in an industry demanding the highest caliber of quality and standards.

From established pioneers to up-and-coming communities, the world of bioscience is transforming into an environment filled with promise and ingenuity. We recognize these regions for their groundbreaking work and expanding ideals in the industry they represent. Discover the positive atmosphere that attracts life science professionals from around the globe.

SPECIAL ADVERTISING SECTION

78 The ScienTiST May 2008

SPECIAL ADVERTISEMENT

METRO ATLANTA CHAMBER OF COMMERCE

FOR MORE INFORMATION, CONTACT:

DAVID HARTNETTVice President, Technology Industry ExpansionMetro Atlanta Chamber of Commerce235 Andrew Young International Blvd.Atlanta, GA 30303T: (404) 586-8458www.AtlantaTechnologyLoop.com

CITY POPULATION: 5,322,915 (Q3, 2007)

TOP THREE REVENUE-GENERATING INDUSTRIES: Professional & Business Services, Retail Trade, Leisure & Hospitality (Q3, 2007)

NO. OF LIFE SCIENCE COMPANIES: 300+ (Q3, 2007)

NO. OF LIFE SCIENCE JOBS: 10,000 (Q4, 2006)

NO. OF INSTITUTIONS OF HIGHER LEARNING: 15 with bio-related programs of study (Q3, 2007)

NO. OF LIFE SCIENCE-FOCUSED VCs: 11 (Q4, 2006)

UNEMPLOYMENT RATE: 5.5% (Q3, 2007)

AVERAGE LIFE SCIENCE ANNUAL INCOME: $61,863 (Q4, 2006)

ATLANTAATL has it ALL for Bioscience

With its pro-business reputation and concen-tration of a young, talented, college-educated workforce, Atlanta is rapidly becoming a recognized leader in the bioscience indus-try. The city jumped from a ranking of 11th to 7th, according to the Ernst & Young Bio-technology Report of 2006, exhibiting the fastest growth in the nation. Atlanta will host BIO2009, the world’s largest biotechnol-ogy conference. From the continuous stream of discoveries coming out of its college and university life science research programs to the partnerships between its non-profit and business communities, Atlanta’s rapidly expanding bioscience industry has bold plans to tackle some of the world’s most pressing health problems.

Which life science companies already conduct business in Atlanta and why did they migrate there?Some life science companies already calling Atlanta home are the CDC, American Cancer Society, Arthritis Foundation, Piedmont Heart Institute, McKesson, Kimberly Clark, CIBA Vision, Yerkes Primate Center, Quest Diagnostics, Quintiles Laboratories, MERIAL Pharmaceuticals, Solvay Pharmaceuticals, CR Bard, UCB Pharma, Porex, CryoLife, Immucor, and Saint Joseph’s Transitional Research Institute. It is often referred to as the “Atlanta Technology Loop”, a hub for the bioscience industry. Bioscience research con-ducted at the region’s world-class universi-

ties is creating new companies and new jobs. A high quality of life and robust economy make metro Atlanta the most popular relo-cation site in America. A strong transporta-tion system and robust telecommunications infrastructure make the region a prime loca-tion for reaching the global marketplace.

What is the lifestyle like?The Metro Atlanta Chamber of Commerce works to grow the economy while ensuring a positive environment and a high quality of life for residents and businesses. Atlanta is host to major attractions such as the Botani-cal Gardens, Six Flags Adventure and the Atlanta Zoo. There are also numerous cul-tural offerings, including the theatre, ballet and orchestra, as well as several museums. Atlanta, ““the sports capital of the U.S.,” is also home to six professional sports fran-chises and state-of-the-art sports facilities.

What are the valuable life science contribu-tions Atlanta has produced?Atlanta is relatively new to the life sci-ences. However, it already houses industry innovators in several fertile areas including bioinformatics, diagnostics, genetic analy-sis and engineering, medical imaging, novel drug discovery and development, vaccine research and therapeutics.

What plans does Atlanta have for expan-sion or revitalizing its draw of life science companies? The Metro Atlanta Chamber of Commerce is committed to helping this industry grow and expand. Its strategic plan includes a recently created Bioscience Industry Council to further support this effort. The council plans to lead the effort in promoting the state and local incentive packages and credits to attract bioscience firms to Atlanta, as well as developing bioscience locations within the city. It will also support and develop the relationship between research universities and commercial companies. n

It Is often referred to as the “Atlanta Technology Loop”, a hub for the bIoscIence Industry.

VISIT US ATBOOTH #1701BIO 2008


THE STATE OF NEW JERSEY


GARY ROSEChief, Office of Economic Growth

125 W. State StreetPO Box 001

Trenton, NJ 08625-0001T: (609) 777-0503

The State of New JerseyT: (866) 534-7789

www.newjerseybusiness.gov

NEW JERSEYA Leader in Innovation

From Edison to Einstein, many of the world’s most revolutionary scientific breakthroughs happened in New Jersey. Today, one of the State’s top priorities is to ensure that New Jersey remains a leader in innovation. New Jersey’s highly educated workforce as well as its’ academic strength provide exceptional opportunities for strate-gic collaborations between the State, private businesses and the nearly 60 universities and colleges that reside here.

What financial/tax incentives does your state offer life science companies?New Jersey offers a variety of financial and tax incentives to life science and technology com-panies to spur innovation, create new, high-paying jobs and cultivate an entrepreneurial environment.

New Jersey’s most comprehensive life science and technology program is the Edison Innovation Fund. Launched in 2006, the Edison Innovation Fund offers a broad range of assistance such as equity-like investments,

tax credits, growth incentives and investments in venture capital funds. The Fund leverages private capital that is targeted to emerging companies with the potential for commercial success, as well as existing mid-size and large technology and life sciences businesses.

Specifically, the Edison Innovation Fund focuses on the growth of core industries vital to the State’s economy including: life sciences, stem cell research, clean energy, new media and communication technologies.

New Jersey’s Business Employment Incentive Program (BEIP) grant is available to expand or relocate life sciences or technol-ogy businesses. Approved businesses receive annual cash grants based on the number of new jobs they create – biotechnology compa-nies must create 10 new jobs within a 2-year period to qualify.

New Jersey also offers a Technology Busi-ness Tax Certificate Transfer Program which is designed to enable approved, unprofitable technology and biotechnology businesses to sell their unused Net Operating Loss (NOL)


STATE POPULATION: 8,685,920

NO. OF LIFE SCIENCES COMPANIES: approximately 1,060

NO. OF LIFE SCIENCES JOBS: Over 400,000 scientists and engineers

NO. OF INSTITUTIONS OF HIGHER LEARNING: 60

NO. OF LIFE SCIENCE-FOCUSED VCs: approximately 15

AVERAGE LIFE SCIENCE INCOME: $122,490

Carryover and unused Research and Devel-opment Tax Credits (R&D Tax Credits) to unaffiliated, profitable corporate taxpayers in New Jersey for at least 75% of the value of the tax benefits. This allows unprofitable technology and biotechnology businesses to turn their tax losses and credits into cash to buy equipment or facilities. In 2007, 92 technology and biotechnology companies were approved to share the $60 million available through the Technology Business Tax Certificate Transfer Program.

Describe the variety of life science compa-nies conducting business in your state.Life science companies in New Jersey range from medical equipment and drug delivery companies to diagnostic imaging centers. The many life sciences companies that call New Jersey home, include:

NeuroTrax Corporation - a medical tech-nology company that designs, develops and markets diagnostic tools for the neurological health care market.Daiichi Sankyo - an emerging leader in car-diovascular care. Novo Nordisk – a world leader in diabetes care.Aptuit – a global company focused on stream-lining and supporting the drug development process for biotechnology and pharmaceuti-cal innovators.Hoffman LaRoche, Inc – the U.S. prescrip-tion drug unit of the Roche Group.Merck & Company – an international devel-oper, manufacturer and distributor of phar-maceuticals.Senesco Technologies – an R&D company specializing in genetic technologies to improve commercial agriculture and treat major medical conditions in humans.Nature’s Choice – a manufacturer of compost, organic fertilizers and mulch.BASF –a major supplier of agricultural products and fine chemicals to the farming, food processing, pharmaceutical, animal

and human nutrition and personal care industries.

Are there certain regions of your state that are more conducive to the growth of life sci-ences than others? Why?Although all of New Jersey is right for the development of the life sciences sector, New Jersey’s Edison Innovation Zones and the State’s Technology Business Incubator Network offer favorable environments and enhanced financial incentives for emerging technology and life science businesses.

The State has three Edison Innovation Zones, located in Camden, the Greater New Brunswick area and Newark that are designed to stimulate collaboration between state universities and the business commu-nity. Within the Greater New Brunswick zone

is one of New Jersey’s biotech “hotbeds,” situated along the Route 1 corridor in Mid-dlesex and Mercer counties. This region is competitive in terms of R&D, with compa-nies locating there to access both Rutgers and Princeton Universities.

Enhanced financial incentives and access to public partnership opportunities are avail-able to technology and life science busi-nesses located within these zones. Incen-tives include a 50 percent lower matching requirement for investments under the

Edison Innovation Fund, as well as lower interest rates on State lending through its Statewide Loan Pool for Business Initiative.

New Jersey supports 13 technology business incubators located throughout the State in conjunction with New Jersey colleges and universities. Incubators offer early-stage bio-technology, chemistry and pharmaceutical companies a way to afford modern laboratory and production facili-ties that can be customized to fit specific research needs. n

log onto the state busIness Web portal at WWW.NEWJERSEYBUSINESS.GOV for more

InformatIon on hoW neW Jersey supports the technology and lIfe scIences IndustrIes.


TORONTO ECONOMIC DEVELOPMENT & TORONTO

REGION RESEARCH ALLIANCE


MATT BUISTManager, Business Development

Medical and BiotechnologyToronto Economic Development

55 John StreetStation 1084, 8th floorToronto, ON M5V 3C6

CanadaT: (416) 392-3380

[email protected]

SAM LEE, PhDDirector, Bio Life Sciences

Toronto Region Research AllianceMaRS Centre

101 College Street, Suite HL30Toronto, ON M5G 1L7

CanadaT: (416) 673-6681

[email protected]

TORONTOA Global Center for R&D

Innovation enhanced with skilled-based collaboration, stable research funding and an impressive record of groundbreaking achievements are propelling Toronto to the forefront of biomedical pre-eminence. Toronto is one of the largest combined bio-medical and biotechnology clusters in North America. With nine universities, twelve research hospitals and numerous private sector research facilities, Toronto offers a wide range of research and business devel-opment opportunities.

A strong foundation of research has led to discoveries such as insulin, the identifi-cation of normal and cancer stem cells, the gene responsible for cystic fibrosis as well as genes associated with Alzheimer’s disease and breast cancer, to name but a few.

“These discoveries are just the tip of an almost 100-year-old iceberg of excellence in both scientific discovery and its application to human disease,” says Toronto native Dr. Alan Bernstein, inaugural executive direc-tor of the Global HIV Vaccine Enterprise in New York City. Bernstein was the found-ing president of the Canadian Institutes of Health Research, Canada’s counterpart to the National Institutes of Health.

The Toronto Area Draw: Public and Private Sector Support for ResearchThe Discovery District, in the heart of Toronto, is a one-square mile research park that includes many university, hospital and independent research facilities, biomedical and biotechnology companies, government, finance and business support services. Each year, more than $1 billion is invested into research in the District. Government tax credits and incentives available to R&D-intensive companies are impressive. Direct Canadian government funding for research now stands at $7.5 billion annually. The Ontario government has committed $730 million for new research in the sector through 2008, and $6.2 billion in Ontario’s post-secondary institutions through 2010. This is one of the world’s best scientific research & experimental development tax benefit programs for companies engaged in R&D activities. For those that qualify, the cost of every $100 invested in R&D can be reduced to $37 or less.

Collaboration Is Key to Toronto’s SuccessCollaboration is pivotal to Toronto’s reputa-tion for innovation and productivity, and it is

REGIONAL POPULATION: 7,200,000 (Q4 2007)

TOP THREE REVENUE-GENERATING INDUSTRIES: Biotech/Pharma (3rd largest in N.A.), IT (4th largest in N.A.), Financial Services (3rd largest in N.A.)

NO. OF LIFE SCIENCE COMPANIES: 1200+ (Q4 2007)

NO. OF LIFE SCIENCE JOBS: 140,000+ (Q4 2007)

NO. OF INSTITUTIONS OF HIGHER LEARNING: 29 with bio-related programs of study (Q4 2007)

NO. OF LIFE SCIENCE-FOCUSED VCs: 31 (Q4 2007)

UNEMPLOYMENT RATE: 6.3% (Q1 2008)

nurtured within more than $1 billion of new research convergence facilities in the Discov-ery District. These include the 750,000 sq. ft. MaRS Centre (a second 750,000 sq. ft. unit is scheduled to open in 2010), the Ter-rence Donnelly Centre for Cellular and Bio-molecular Research, the Leslie Dan Faculty of Pharmacy, the new Centre for Addiction and Mental Health CNS Campus, and the McEwen Centre for Regenerative Medicine. These facilities position Toronto as a global leader and partner in advanced biotechnology research and commercialization.

All of these compelling attributes are attracting leading researchers to the Toronto area. Dr. Tom Hudson came from Montreal via Boston to lead the new Ontario Institute for Cancer Research (OICR). Dr. Hudson and his multi-disciplinary research team were found-ing members of the International Haplotype Map Consortium, which made a major con-tribution to the international human genome program. OICR focuses on translating health research into treatments, devices, procedures and services that will benefit cancer preven-tion and treatment. OICR’s budget for its first five years is $347 million.

“It is very exciting to be leading the research which will have a significant impact on controlling cancer,” says Hudson. “We are very fortunate that Ontario has world-leading capability in cancer research, and we are able to build on that to achieve our goals.”

Toronto: A World Leader in Stem Cell ResearchTwo Toronto-based researchers, Drs. Ernest McCulloch and James Till, set the stage for modern stem cell research when they discov-ered blood forming stem cells that enabled bone marrow transplants. The region is now home to other leading stem cell researchers: Dr. John Dick discovered cancer stem cells in leukemia and colon cancers; Dr. Peter Dirks identified cancer stem cells in brain tumors; and Dr. Gordon Keller discovered hemato-poietic, vascular and cardiac lineages from embryonic stem cells. They are joined by

other researchers whose work contributes to making the region a world-class hub for stem cell investigation: Drs. Janet Rossant, Andras Nagy, Bob Casper, Armand Keating and Peter Zandstra. The region will soon host Canada’s first human embryonic stem cell library to be led by Dr. Mick Bhatia at McMaster Universi-ty’s Michael G. DeGroote Centre for Learning and Discovery in nearby Hamilton, Ontario.

The future of stem cell research in the region is bright. Last year, California Gover-nor Arnold Schwarzenegger visited Toronto and, together with Ontario Premier Dalton McGuinty, announced the Cancer Stem Cell Consortium, with the Canadian part based in Toronto. Ontario will contribute $30 million to the Consortium to support the discovery and development of new therapies for cancer. Partners in this new initiative include UC

Berkeley’s Stem Cell Center in California, and Ontario-based OICR and the International Regulome Consortium.

Toronto’s immense research and develop-ment opportunities continue to attract global attention. “Toronto’s health research commu-nity is simply one of the best anywhere,” says Dr. Bernstein. n

the ontarIo government has commItted $730 MILLION FOR NEW RESEARCH IN THE

SECTOR THROUGH 2008, and $6.2

bIllIon In ontarIo’s post-secondary

InstItutIons through 2010.


AMSTERDAM INNOVATION MOTOR


SANDRA MIGCHIELSENProject Manager Life Sciences

de Ruyterkade 51013 AA Amsterdam

T: +31 20 5241123F: +31 20 5241134

M: +31 [email protected]

Amsterdam Innovation Motor www.aimsterdam.nl/

www.amsterdambiomed.nl

AMSTERDAMA Sleeping Giant is Waking Up!

Find your life sciences partner in Amsterdam BioMedAmsterdam ranks fifth in the overall rating of best European cities for business (European Cities Monitor 2007, Cushman & Wakefield), due to its languages spoken, the availability of qualified staff, easy access to markets and customers, and national and international transport links. Then again, Amsterdam is more than the financial, service and tourist center it is famous for. Biobusiness is finally booming in Europe, and Amsterdam doesn’t lag behind thanks to the strong biomedical knowledge and technology base of the city’s universities and research institutes. The Amsterdam Metropolitan Area has a mature company structure in which all type of organi-zations that together make up the life sciences business chain are well represented and have multiple interactions. Well equipped as well in terms of technology infrastructure, science parks, technology transfer support and funding opportunities, one could say that all ingredients for growth and success in life sci-ences are available here. Amsterdam BioMed – the regional platform to facilitate and accel-erate industry developments – is your point of entry to Amsterdam life sciences.

What financial/tax incentives does Amster-dam offer to life science companies?The Dutch government offers several appealing subsidy opportunities for foreign investors. Under the R&D Promotion Act “WBSO”, a contribution is paid towards the wage costs of employees directly involved in R&D.

The Dutch tax system is transparent and stable and encourages a favorable inward investment climate. In European terms, the Netherlands levies a low rate of tax on profits, as well as an exemption regulation that applies to the profits of (international) companies above a certain level. Tax trea-ties have been arranged with nearly all major trade countries to prevent double levies, and the Dutch tax inspector is prepared to make advance agreements with new ventures con-cerning their expected tax burden.

Expats benefit too: 30% of their Dutch income is exempt from tax. Moreover, within the framework of the knowledge migrants’ scheme, expats and their families qualify for an accelerated application procedure for resi-dential and work permits.

More than 1,400 foreign companies have set up office in Amsterdam.


What is the lifestyle in Amsterdam?Amsterdam ranks 4th in the European ranking of most livable capitals (Mercer Human Resource Consulting, 2007).

Thanks to the relatively low cost of living, good and affordable international schools and a ready supply of business and living space, Amsterdam has plenty to offer in material terms. Amsterdam offers all the advantages of a cosmopolitan city and busi-ness centre, but on an intimate scale. The work-life balance that results is prized by everyone.

With 174 different nationalities Amster-dam is a true global village. The local profes-sional population is multilingual, multicultural, tolerant, and independent-minded.

What draws life science companies to Amsterdam?Amsterdam has the highest concentration of life sciences research in the Netherlands with a strong biomedical focus. The city is home to two universities, with academic hospitals, and numerous specialized research insti-tutes. Together they provide industry with easy access to many innovative technologies, huge clinical trial capabilities, patient cohorts, biobanks and many expert centres.

A long tradition of excellence exists in five therapeutic areas: oncology, neurosci-ences, autoimmunity, and cardiovascular and infectious diseases. More than 70 dedi-cated Life Sciences companies have already chosen to set up office in Amsterdam and the Amsterdam Metropolitan Area, includ-ing multiple university spin offs. To gain eco-nomical spin off of the bio- and medical tech-nology in the Amsterdam Metropolitan Area various activities are undertaken, and clus-tered under the label Amsterdam BioMed. Within the Life Sciences Centre Amsterdam techtransfer opportunities coming from the capital’s biomedical research institutes are combined and commercialized together. The institutes involved are the University of Amsterdam/ Swammerdam Institute of Life

Sciences, the Netherlands Cancer Institute, Academic Medical Centre, VU University Amsterdam/ VU University Medical Centre, and Sanquin.

A serious appetite with investors for biotech companies currently exists. More-over, the number of listed European biotech companies more than doubled (from 10 to 25) since 2004 on the NYSE Euronext European platform. Of all European regions, the Benelux reported the highest number of IPOs by biotech companies in 2007. Within the Amsterdam Metropolitan Area entrepreneurs have access to a number of professional support- and funding options, of which Iamstarter and the Life Sciences Fund Amsterdam constitute dedicated

and decisive assets for the growth of the regional industry.

The Amsterdam BioMed Cluster is the regional network organization for Life Sci-ences bringing together businesses, aca-demia, service providers, investors and local government.

By opening up the regional knowledge- and technology base, online via www.amster-dambiomed.nl, national and international parties are invited to do business with us.

The Amsterdam Metropolitan Area offers a number of locations with office and labora-tory space specifically aimed at life sciences activities, as well as access to a wide range of services and tools. n

amsterdam has the HIGHEST

CONCENTRATION OF LIFE SCIENCES research In the

netherlands WIth a strong bIomedIcal

focus.

CITY POPULATION: Amsterdam 744,000, Amsterdam Metro Area: 2,107,000 (Q4, 2007)

TOP THREE REVENUE-GENERATING INDUSTRIES: Business Services, Financial Services, Wholesale (Q4, 2007)

NO. OF LIFE SCIENCE COMPANIES: 70+ dedicated life sciences companies (Q4, 2007)

NO. OF INSTITUTIONS OF HIGHER LEARNING: 12 (Q4, 2007)

NO. OF LIFE SCIENCE-FOCUSED VCs: 9 (Q4, 2007)

UNEMPLOYMENT RATE: 6.7% (Q1, 2008)

PALM BEACH COUNTYInnovation. Works. Here.

Palm Beach County is the heart of Florida’s emerging life science and bio-tech center with more than 140 companies focused on the discovery and advancement of drugs and pharmaceuticals, medical devices and equip-ment, research and testing.

Anchored by two world-class research-ers, Max Planck Institute, Florida, and Scripps, Florida, Palm Beach County is creating a powerful environment where biotech companies expand, relocate and thrive. Strong collaborations exist among universities, pro-active assistance pro-grams are available and a wealthy demographic base provides access to philanthropic dollars.

What draws life science companies to Palm Beach County? Companies say Palm Beach County is an ideal place to take their research discoveries from the lab to the marketplace. The area’s strength in biotechnology and biomedical industries can be attributed to its existing research and

development infrastructure, top notch edu-cational facilities with robust science and biotechnical programs and the support of an entrepreneurial environment. Plans are underway to help identify new recruits to the county in basic research, clinical research and production. Scripps Florida will officially open in Jupiter, Fla., in early 2009. The Business Development Board of Palm Beach County will attend BIO2008 to reinforce these efforts. n

COUNTY POPULATION: 1,323,572 (Q4 2007)

NO. OF LIFE SCIENCE COMPANIES: 140+ (Q4 2007)

NO. OF LIFE SCIENCE JOBS: 12,245+ (Q4 2007)

NO. OF INSTITUTIONS OF HIGHER LEARNING: 7

AMOUNT OF VC LIFE SCIENCE SPENDING: $1.64 million (Q4 2007)

UNEMPLOYMENT RATE: 4.1% (Q4 2007)

AVERAGE ANNUAL LIFE SCIENCE REVENUE:

$1,713,102,141 (Q4 2007)

BUSINESS DEVELOPMENT BOARD OF PALM BEACH COUNTY


ANDREW DUFFELLSenior Vice President

Business Recruitment, Retention & ExpansionBusiness Development Board

of Palm Beach County, Inc.310 Evernia Street

West Palm Beach, Florida 33401T: +1 (561) 835-1008F: +1 (561) 651-4136

C: +1 (561) [email protected]

www.bdb.org

SPECIAL ADVERTISEMENTVISIT US ATBOOTH #1911BIO 2008

forbes.com reports palm

beach county ranks #3

on Its top 10 lIst of “HOTBEDS OF

TOMORROW’S TECHNOLOGY.”

“I think that in Florida, Max Planck can make a dif-ference. We can build together with Scripps and Florida Atlantic University, a first class research center. So it is very evident that the quality of life you have here and the possibility to recruit talent – the critical mass that the three of us can provide together will allow us to have a world leading insti-tute.” —Dr. Peter Gruss, Max Planck Society

“I think when Scripps was looking for an area, of course, they wanted someplace that could accommodate the facilities – a science campus – but also the other attributes that would be important to attracting world class faculty here: The environment and the culture, those also played into the decision.” —Dr. Harry Orf, Scripps Florida

bioscience atlas 2008€¦ · hoffman laroche, inc – the u.s. prescrip-tion drug unit of the...

Documents